A novel best-case scenario cost-benefit analysis showed very conservatively that there are five times the number
of deaths attributable to each inoculation vs those attributable to COVID-19 in the most vulnerable 65+ demographic. The risk of death from COVID-19 decreases drastically as age decreases, and the longer-term effects
of the inoculations on lower age groups will increase their risk-benefit ratio, perhaps substantially.
Further,
the clinical trials did not address changes in biomarkers that could serve as early warning indicators of elevated
predisposition to serious diseases. Most importantly, the clinical trials did not address long-term effects that, if
serious, would be borne by children/adolescents for potentially decades.
No comments:
Post a Comment